Oncohematología y Genética

Biología molecular del cáncer

Amancio Carnero Moya
Amancio Carnero Moya
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla

Laboratorio: 214

Amancio Carnero Moya

Volver al programa
  1. Miembros del grupo
  2. Áreas de trabajo
  3. Publicaciones

Grupo: Biología molecular del cáncer

Directorio
Miembros del grupo Biología molecular del cáncer
  • Carnero Moya, Amancio.Investigador Cientifico CSIC. Doctor en Biología Molecular
  • Chaves Conde, Manuel.Doctor en Medicina. Facultativo clínico
  • Clemente González, Cynthia.Investigadora Predoctoral
  • Espinosa Sánchez, Asunción .Investigadora Predoctoral. Beca AECC.
  • Estévez García, Purificación.Doctora en Medicina. Oncóloga Clínica
  • Fuentes Pradera, José.FEA HUV Valme
  • García Heredia, José Manuel.Profesor ayudante doctor en Bioquímica
  • Marín López, Juan José.Profesor Contratado Doctor Interino en Biología
  • Martínez Pérez, Julia.Río Hortega. Doctora en Biología Molecular, Biomedicina e Investigación Clínica
  • Muñoz Galván, Sandra.Investigadora Postdoctoral. Doctora en Biología
  • Navas Maldonado, Lola Eufemia.Investigadora en Formación
  • Otero Albiol, Daniel.Estudiante Predoctoral.Doctor en Biología Molecular, Biomedicina e Investigación Clínica
  • Peinado Serrano, Javier.Ldo. en Medicina
  • Sánchez Díaz, Laura.Lda. en Biomedicina básica y experimental
  • Suárez Martínez, Elisa.Lda. en Biomedicina. Predoctoral.
  • Suazo Sánchez, Irene.Técnico de Apoyo
  • Vázquez Gutiérrez, Inmaculada.Contratada FPI
  • Verdugo Sivianes, Eva Mª.Investigadora en Formación. Doctora en Biología Molecular

Áreas de trabajo

 

 LOGO FEDER

 

 

TÍTULO DEL PROYECTO: Identificación y caracterización de factores genéticos y fisiológicos involucrados en senescencia celular. Relevancia clínica en cáncer.

 

RESUMEN: (Objetivo, diseño, ámbito del estudio, sujetos de estudio, instrumentación, resultados, conclusiones)

La senescencia celular es un mecanismo supresor de tumores que debe ser anulado durante el proceso de tumorigénesis. Todos los tumores llevan alteraciones que contribuyen a evitar la senescencia. Entender el proceso de senescencia es importante no sólo para descubrir la fisiología de las células somáticas, y su contraparte normal inmortal, las células madre, sino más relevante para ser capaz de identificar nuevas alteraciones genéticas y epigenéticas que proporcionan nuevos genes supresores de tumores u oncogenes que pueden actuar como biomarcadores de diferenciación entre tumores benignos y malignos, nuevos biomarcadores con valor pronóstico o predictivo. Para generar nuevos métodos para identificar tumores en etapas tempranas, para identificar nuevas dianas moleculares y fisiológicas adecuadas para la intervención terapéutica y el control de la enfermedad. Por lo tanto en nuestro proyecto planeamos un estudio en profundidad de los nuevos procesos fisiológicos implicados en la senescencia celular a través de los nuevos genes descubiertos en nuestro laboratorio. Estos nuevos genes pertenecen a familias funcionales implicadas en transportadores y canales iónicos de membrana, sistemas de degradación de proteínas y autofagia, oxidación e hipoxia, metabolismo y long non coding RNAs. Tenemos la intención de estudiar estas nuevas alteraciones genéticas, su papel en la inmortalización y la tumorigénesis, su papel como biomarcadores pronósticos o predictivos y su viabilidad para ser utilizado como nueva diana para el tratamiento contra el cáncer. También planeamos estudiar la pertinencia de la senescencia celular en la carcinogénesis medioambiental ycómo podemos revertir el fenotipo utilizando la senescencia como punto final para la terapia antitumoral.

 

ÁREAS DE TRABAJO GENERALES 

 

Nuestro laboratorio ha centrado sus esfuerzos en 2 vías paralelas. Por un lado la medicina de precisión, con especial hincapié en biomarcadores predictivos de eficacia y biomarcadores pronóstico en distintos modelos tumorales. Por otro lado hemos seguido desarrollando nuestra búsqueda y caracterización de nuevas alteraciones genéticas y epigenéticas que tengan relevancia en cáncer. En estos sentidos hemos avanzado en las siguientes areas.

  • NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP.

Purpose: Colorectal cancer is the second most common cancer in women and the third most common in men worldwide. However, despite current progress, many patients with advanced and metastatic tumors still die from the malignancy. Refractory disease often relies on nicotinamide adenine dinucleotide (NAD)-dependent mechanisms. NAD metabolism and a stable NAD regeneration circuit are required to maintain tissue homeostasis and metabolism. However, high levels of NAD confer therapy resistance to tumors.Experimental Design: Ectopic overexpression of nicotinamide phosphoribosil transferase (NAMPT) and shRNAs in colorectal cancer cell lines, tumorigenic and stemness properties and transcription measurement in culture and in vivo Transcriptional analysis in public databases. Therapeutic approaches.Results: NAMPT, the rate-limiting enzyme responsible for the highest source of physiologic NAD biosynthesis, increases tumorigenic properties and induces cancer stem cell-like properties through pathways that control stem cell signaling, thus enriching the cancer-initiating cell (CIC) population. Furthermore, NAMPT expression correlated with high levels of CIC-like cells in colon tumors directly extracted from patients, and transcription meta-analysis revealed that NAMPT is also a key factor that induces cancer stem pathways in colorectal cancer tumors. This effect is mediated by PARP and SIRT1. In addition, we report a novel NAMPT-driven signature that stratifies prognosis from high to low expression groups. The NAMPT signature contained SIRT1 and PARP1 levels as well as other cancer stem cell-related genes. Finally, NAMPT inhibition increased the sensitivity to apoptosis in both NAMPT-expressing cells and tumorspheres.Conclusions: NAMPT represents a novel therapeutic target in colon cancer progression and relapse, particularly the CIC subset of human colon cancers.

  • NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.

Gliomas are the most prevalent primary malignant brain tumors associated with poor prognosis. NAMPT, a rate-limiting enzyme that boosts the nicotinamide adenine dinucleotide (NAD) regeneration in the salvage pathway, is commonly expressed in these tumors. NAD metabolism is required to maintain tissue homeostasis. To maintain metabolism, cancer cells require a stable NAD regeneration circuit. However, high levels of NAD confer resistance to therapy to these tumors, usually treated with Temozolomide (TMZ). We report that NAMPT overexpression in glioma cell lines increases tumorigenic properties controlling stem cell pathways and enriching the cancer-initiating cell (CIC) population. Furthermore, NAMPT expression correlated with high levels of Nanog, CD133 and CIC-like cells in glioblastoma directly extracted from patients. Meta-analysis reveals that NAMPT is also a key factor inducing cancer stem pathways in glioma cells. Furthermore, we report a novel NAMPT-driven signature which stratify prognosis within tumor staging. NAMPT signature also correlates directly with EGFR positive and IDH negative tumors. Finally, NAMPT inhibition increases sensitivity to apoptosis in both NAMPT-expressing cells and tumorspheres. Therefore, NAMPT represents a novel therapeutic target in Glioma progression and relapse.

  • The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.

Purpose: Cancer stem cells (CSC) are self-renewing tumor cells, with the ability to generate diverse differentiated tumor cell subpopulations. They differ from normal stem cells in the deregulation of the mechanisms that normally control stem cell physiology. CSCs are the origin of metastasis and highly resistant to therapy. Therefore, the understanding of the CSC origin and deregulated pathways is important for tumor control.Experimental Design: We have included experiments in vitro, in cell lines and tumors of different origins. We have used patient-derived xenografts (PDX) and public transcriptomic databases of human tumors.Results: MAP17 (PDZKIP1), a small cargo protein overexpressed in tumors, interacts with NUMB through the PDZ-binding domain activating the Notch pathway, leading to an increase in stem cell factors and cancer-initiating-like cells. Identical behavior was mimicked by inhibiting NUMB. Conversely, MAP17 downregulation in a tumor cell line constitutively expressing this gene led to Notch pathway inactivation and a marked reduction of stemness. In PDX models, MAP17 levels directly correlated with tumorsphere formation capability. Finally, in human colon, breast, or lung there is a strong correlation of MAP17 expression with a signature of Notch and stem cell genes.Conclusions: MAP17 overexpression activates Notch pathway by sequestering NUMB. High levels of MAP17 correlated with tumorsphere formation and Notch and Stem gene transcription. Its direct modification causes direct alteration of tumorsphere number and Notch and Stem pathway transcription. This defines a new mechanism of Notch pathway activation and Stem cell pool increase that may be active in a large percentage of tumors.

 

 

  • The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.

Inflammation is a complex defensive response activated after various harmful stimuli allowing the clearance of damaged cells and initiating healing and regenerative processes. Chronic, or pathological, inflammation is also one of the causes of neoplastic transformation and cancer development. MAP17 is a cargo protein that transports membrane proteins from the endoplasmic reticulum. Therefore, its overexpression may be linked to an excess of membrane proteins that may be recognized as an unwanted signal, triggering local inflammation. Therefore, we analyzed whether its overexpression is related to an inflammatory phenotype. In this work, we found a correlation between MAP17 expression and inflammatory phenotype in tumors and in other inflammatory diseases such as Crohn's disease, Barrett's esophagus, COPD or psoriasis. MAP17 expression correlated also with the markers of inflammation HLAs, BBS10, HERC2, ADNP and PYCARD. Furthermore, we found that MAP17 expression directly regulates NFAT2 and IL-6 activation, inducing the differentiation of monocytes to dendritic cells and suggesting a causal role of MAP17 in inflammation. Immunohistochemistry confirms local inflammation, mainly CD45+ cells, at the site of expression of MAP17, at least in tumors, Crohn's and psoriasis. Therefore, our data indicates that the overexpression of the protein MAP17 plays important role in diseases involving chronic inflammation.

  • Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.

The PIM family of Ser/Thr kinase proteins has been implicated in tumorigenesis at different levels. PIM proteins are overexpressed in several tumor types and have been associated with chemoresistance. However, their role in hormone-dependent female tissues has not been explored, especially in the uterus, breast and ovary. We generated conditional transgenic mice with confined expression of human PIM1 or PIM2 genes in these tissues. We characterized the tumoral response to these genetic alterations corroborating their role as oncogenes since they induce hyperproliferation in all tissues and tumors in mammary gland and uterus. Furthermore, we observed a high degree of inflammatory infiltration in these tissues of transgenic mice accompanied by NFAT and mTOR activation and IL6 expression. Moreover, PIM1/2 were overexpressed in human breast, uterine and ovarian tumors, correlating with inflammatory features and stem cell markers. Our data suggest that PIM1/2 kinase overexpression provoke tissue alterations and a large IL6-dependent inflammatory response that may act synergistically during the process of tumorigenesis. The possible end-point is an increased percentage of cancer stem cells, which may be partly responsible for the therapy resistance found in tumors overexpressing PIM kinases.

  • Genome-Wide miRNA Screening for Genes Bypassing Oncogene-Induced Senescence.

MicroRNAs are small noncoding RNAs that regulate gene expression by binding to sequences within the 3'-UTR of mRNAs. Genome-wide screens have proven powerful in associating genes with certain phenotypes or signal transduction pathways and thus are valuable tools to define gene function. Here we describe a genome-wide miRNA screening strategy to identify miRNAs that are required to bypass oncogene-induced senescence.

  • Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.

The scaffold protein Spinophilin (Spinophilin, PPP1R9B) is one of the regulatory subunits of phosphatase-1 (PP1), directing it to distinct subcellular locations and targets. The loss of Spinophilin reduces PP1 targeting to pRb, thereby maintaining higher levels of phosphorylated pRb. Spinophilin is absent or reduced in approximately 40% of human lung tumors, correlating with the malignant grade. However, little is known about the relevance of the coordinated activity or presence of Spinophilin and its reported catalytic partners in the prognosis of lung cancer. In the present work, we show that the downregulation of Spinophilin, either by protein or mRNA, is related to a worse prognosis in lung tumors. This effect is more relevant in squamous cell carcinoma, SCC, than in adenocarcinoma. Downregulation of Spinophilin is related to a decrease in the levels of its partners PPP1CA/B/C, the catalytic subunits of PP1. A decrease in these subunits is also related to prognosis in SCC and, in combination with a decrease in Spinophilin, are markers of a poor prognosis in these tumors. The analysis of the genes that correlate to Spinophilin in lung tumors showed clear enrichment in ATP biosynthesis and protein degradation GO pathways. The analysis of the response to several common and pathway-related drugs indicates a direct correlation between the Spinophilin/PPP1Cs ratio and the response to oxaliplatin and bortezomib. This finding indicates that this ratio may be a good predictive biomarker for the activity of the drugs in these tumors with a poor prognosis.

  • Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.

Lung tumors represent a major health problem. In early stage NSCLC tumors, surgical resection is the preferred treatment, but 30-55% of patients will relapse within 5 years after surgery. Thus, the identification of prognostic biomarkers in early stage NSCLC patients, especially those which are therapeutically addressable, is crucial to enhance survival of these patients. We determined the immunohistochemistry expression of key proteins involved in tumorigenesis and oncogenic signaling, p53, EGFR, pAKT and pERK, and correlated their expression level to clinicopathological characteristics and patient outcome. We found EGFR expression is higher in the squamous cell carcinomas than in adenocarcinomas (p=0.043), and that nuclear p53 staining correlated with lower differentiated squamous tumors (p=0.034). Regarding the prognostic potential of the expression of these proteins, high pERK levels proved to be an independent prognostic factor for overall (p<0.001) and progression-free survival (p<0.001) in adenocarcinoma patients, but not in those from the squamous histology, and high p53 nuclear levels were identified as independent prognostic factor for progression-free survival (p=0.031) only in squamous cell carcinoma patients. We propose a role as early prognostic biomarkers for pERK protein levels in adenocarcinoma, and for nuclear p53 levels in squamous cell lung carcinoma. The determination of these potential biomarkers in the adequate histologic context may predict the outcome of early stage NSCLC patients, and may offer a therapeutic opportunity to enhance survival of these patients.

Revistas Internacionales
Martin-Broto, J; Hindi, N; Lopez-Pousa, A; Peinado-Serrano, J; Alvarez, R; Alvarez-Gonzalez, A; Italiano, A; Sargos, P; Cruz-Jurado, J; Isern-Verdum, J; Dolado, MC; Rincon-Perez, I; Sanchez-Bustos, P; Gutierrez, A; Romagosa, C; Morosi, C; Grignani, G; Gatti, M; Luna, P; Alastuey, I; Redondo, A; Belinchon, B; Martinez-Serra, J; Sunyach, MP; Coindre, JM; Dei Tos, AP; Romero, J; Gronchi, A; Blay, JY; Moura, DS
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial
JAMA ONCOLOGY
Cayuela, L; Lendinez-Cano, G; Chavez-Conde, M; Rodriguez-Dominguez, S; Cayuela, A
Recent trends in prostate cancer in Spain
ACTAS UROLOGICAS ESPANOLAS
Macias-Garcia, L; Martinez-Ballesteros, M; Luna-Romera, JM; Garcia-Heredia, JM; Garcia-Gutierrez, J; Riquelme-Santos, JC
Autoencoded DNA methylation data to predict breast cancer recurrence: Machine learning models and gene-weight significance
ARTIFICIAL INTELLIGENCE IN MEDICINE
Quintanal-Villalonga, A; Ferrer, I; Guruceaga, E; Cirauqui, C; Marrugal, A; Ojeda, L; Garcia, S; Zugazagoitia, J; Munoz-Galvan, S; Lopez-Rios, F; Montuenga, L; Vicent, S; Molina-Pinelo, S; Carnero, A; Paz-Ares, L
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
EBIOMEDICINE
Garcia-Heredia, JM; Otero-Albiol, D; Perez, M; Perez-Castejon, E; Munoz-Galvan, S; Carnero, A
Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells
ONCOGENESIS
Perez, M; Garcia-Heredia, JM; Felipe-Abrio, B; Munoz-Galvan, S; Martin-Broto, J; Carnero, A
Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Marques, M; Tranchant, R; Risa-Ebri, B; Suarez-Solis, ML; Fernandez, LC; Carrillo-de-Santa-Pau, E; Del Pozo, N; de Villarreal, JM; Meiller, C; Allory, Y; Blum, Y; Pirker, C; Hegedus, B; Barry, ST; Carnero, A; Berger, W; Jean, D; Real, FX
Combined MEK and PI3K/p110 beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
CANCER RESEARCH
Munoz-Galvan, S; Felipe-Abrio, B; Verdugo-Sivianes, EM; Perez, M; Jimenez-Garcia, MP; Suarez-Martinez, E; Estevez-Garcia, P; Carnero, A
Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness
MOLECULAR CANCER
Perez-Martinez, L; Romero, L; Munoz-Galvan, S; Verdugo-Sivianes, EM; Rubio-Mediavilla, S; Oteo, JA; Carnero, A; Blanco, JR
Implications of maraviroc and/or rapamycin in a mouse model of fragility
AGING-US
Espinosa-Sanchez, A; Suarez-Martinez, E; Sanchez-Diaz, L; Carnero, A
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
FRONTIERS IN ONCOLOGY
Marin-Barrera, L; Munoz-Martin, AJ; Rios-Herranz, E; Garcia-Escobar, I; Beato, C; Font, C; Oncala-Sibajas, E; Revuelta-Rodriguez, A; Areses, MC; Rivas-Jimenez, V; Moreno-Santos, MA; Ballaz-Quincoces, A; Lopez-Saez, JB; Gallego, I; Elias-Hernandez, T; Asensio-Cruz, MI; Chasco-Eguilaz, L; Garcia-Gonzalez, G; Estevez-Garcia, P; Otero, R; Lima-Alvarez, J; Jara-Palomares, L
A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study
CANCERS
Felipe-Abrio, B; Carnero, A
The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness
CANCERS
Munoz-Galvan, S; Rivero, M; Peinado-Serrano, J; Martinez-Perez, J; Fernandez-Fernandez, MC; Ortiz, MJ; Garcia-Heredia, JM; Carnero, A
PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208
CELLS
Munoz-Galvan, S; Carnero, A
Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer
CELLS
Garcia-Heredia, JM; Carnero, A
Role of Mitochondria in Cancer Stem Cell Resistance
CELLS
Lopez-Medina, EM; Sainz, T; de Ory, SJ; Mellado-Pena, MJ; Gonzalez-Tome, MI; Gil, EC; Cucurull, TV; Neyra, F; Frick, MA; Martinez-Perez, J; Andres, AGA; Alonso, MB; Laleona, CG; Hernandez, MM; Hernandez, PC; Amador, JTR; Gomez, MLN; Santiago-Garcia, B
Tuberculosis in a Spanish cohort of children living with HIV: the CHOTIS study (Childhood HIV & TB study)
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, García-Heredia JM, Pérez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
. J Exp Clin Cancer Res.
García-Heredia JM, Carnero A.
Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases
Mol Cancer.
Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, Muñoz-Galván S, Carnero A.
NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP.
Clin Cancer Res.
Molina-Pinelo S, Salinas A, Moreno-Mata N, Ferrer I, Suárez R, Andrés-León E, Rodríguez-Paredes M, Gutekunst J, Jantus-Lewintre E, Camps C, Carnero A, Paz-Ares L.
Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.
Oncotarget
Quintanal-Villalonga Á, Mediano M, Ferrer I, Meléndez R, Carranza-Carranza A, Suárez R, Carnero A, Molina-Pinelo S, Paz-Ares L.
Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.
Oncotarget
Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S, Paz-Ares L.
The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.
Sci Rep
Pachón Ibáñez J, Pereira Cunill JL, Osorio Gómez GF, Irles Rocamora JA, Serrano Aguayo P, Quintana Ángel B, Fuentes Pradera J, Chaves Conde M, Ortiz Gordillo MJ, García Luna PP.
Prevention of oral mucositis secondary to antineoplastic treatments in head and neck cancer by supplementation with oral glutamine
Nutr Hosp.
García-Heredia JM, Carnero A.
NUMB and NUMBL differences in gene regulation.
Oncotarget
Rivero M, Peinado-Serrano J, Muñoz-Galván S, Espinosa-Sánchez A, Suárez-Martínez E, Felipe-Abrio B, Fernández-Fernández MC, Ortiz MJ, Carnero A.
MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy.
Oncotarget.
García-Heredia JM, Lucena-Cacace A, Verdugo-Sivianes EM, Pérez M, Carnero A.
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
Clin Cancer Res.
García-Heredia JM, Carnero A.
The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment
Oncotarget.
Jiménez-García MP, Lucena-Cacace A, Robles-Frías MJ, Ferrer I, Narlik-Grassow M, Blanco-Aparicio C, Carnero A.
Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.
Oncotarget
Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, Peinado-Serrano J, Carnero A.
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis
Oncotarget.
Martín-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, García Del Muro X, Gutiérrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martínez-Trufero J, Díaz-Beveridge R, Cruz J, Encinas V, Tarón M, Moura DS, Luna P, Hindi N, López-Pousa A.
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Ann Oncol.
Verdugo-Sivianes EM, Navas L, Molina-Pinelo S, Ferrer I, Quintanal-Villalonga A, Peinado J, García-Heredia JM, Felipe-Abrio B, Muñoz-Galván S, Marín JJ, Montuenga L, Paz-Ares L, Carnero A.
Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.
Oncotarget
Martínez-Pérez J, López-Calderero I, Sáez C, Benavent M, Limón ML, González-Expósito R, Soldevilla B, Riesco-Martínez MC, Salamanca J, Carnero A, García-Carbonero R.
Prognostic relevance of Src activation in stage II-III colon cancer
Hum Pathol.
Guijarro MV, Carnero A.
Genome-Wide miRNA Screening for Genes Bypassing Oncogene-Induced Senescence
Methods Mol Biol